ASCO 2024 | Immune microenvironment evolution in breast cancer brain metastases

Gaia Griguolo • 5 Jun 2024

ASCO 2024

Breast Cancer

Gaia Griguolo, MD, University of Padova, Padova, Italy, examines the changes in the tumor immune microenvironment (TIME) from primary breast cancer to brain metastases using multiplex immunofluorescence. The study identifies a more immunosuppressive TIME in brain metastases, characterized by reduced lymphocytic and cytotoxic cell infiltration, increased immunosuppressive markers, and higher macrophagic infiltration. These findings suggest that breast cancer brain metastases have an immunosuppressed phenotype, potentially guiding future immunotherapeutic strategies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – Gilead Sciences; Menarini; Seagen
Speakers’ Bureau – Lilly; MSD
Travel, Accommodations, Expenses – Amgen; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer